The bone graft substitutes market is shifting towards more expensive materials, according to a new iData report.
Here are seven key trends in the bone graft substitutes market:
1. The market was valued at more than $850 million last year as the shift toward more expensive demineralized bone matrix and synthetic graft products began.
2. Alternative graft options to the autograft bone are more desirable because autograft bone requires two incisions and increased operative time.
3. There is strong growth in the synthetic materials because of improved handling characteristics and the unit sales growth of complementary orthopedic cell therapy products acts as a driver for the synthetic graft procedure numbers.
4. One of the driving factors of demineralized products is that demineralization can make grafts more osteoinductive in exchange for osteoconductivity as compared to allografts.
5. Currently, there is little difference between each brand in the DBM market, but companies can add value to products with the carrier packaging and delivery method.
6. Medtronic leads the bone graft substitute market with nearly 20 percent of the market share in 2014. The company has a presence in both the demineralized bone graft and synthetic bone graft markets. Medtronic is also a leader in spinal fusions, which is an effective sales channel for bone graft substitute products.
7. Other leading companies include DePuy Synthes, Stryker, Integra LifeSciences, TRI Surgical, MTF, AlloSource, Baxter, Biomet, Wright Medical, Bacterin, LifeNet Health, Biocomposites, Exactech, Arthrex, Alphatec Spine, Berkeley Advanced Biomaterials, Etex and Osteogenics.